Dr Reddy's Laboratories (DRREDDY) Weekly Analysis
Price & Volume
The stock price experienced a minor upward movement of 0.28% during the week ending April 17, 2026. Trading activity increased significantly, with total volume rising by 27.43% compared to the previous week. The price remained near both the 50-day and 200-day moving averages, which are the average closing prices over the last 50 and 200 trading days.
Technicals
The stock closed at 1235.7 this week, reflecting a 0.28% increase. The 50-day moving average, which tracks the average price over 50 days to show the medium-term trend, is sloping upward. The Relative Strength Index (RSI), a measure of momentum that ranges from 0 to 100, sits at 47.42, indicating neutral momentum. Bollinger Band width, which measures volatility or price fluctuations, is at 10.98%. Overall, the market shows a neutral momentum profile with price trading slightly below the 50-day moving average, reflecting a period of consolidation within the current technical regime.
Fundamentals
Dr Reddy's Laboratories shows a steady long-term growth profile, with revenue reaching 32,644 [Mar 2025], reflecting a 14.9% 3-year CAGR (compound annual growth rate, representing the smoothed annual growth over three years). Profitability remains notable, with net profit at 5,725 [Mar 2025], supported by a 37.9% 3-year CAGR. However, the most recent quarter (Dec 2025) indicates a 15.2% YoY decline in net profit, highlighting recent volatility. The company maintains a solid financial position with a net debt-to-EBITDA ratio of 0.5 [Mar 2025], indicating a low level of debt relative to operating earnings. Overall, the firm demonstrates significant multi-year expansion, though recent quarterly results show a temporary softening in earnings performance.
News
During the week ending April 19, 2026, Dr. Reddy’s Laboratories experienced several corporate developments. On April 15, 2026, the company announced that its Russian subsidiary received a reduced tax penalty of RUB 9.27 million. Subsequently, on April 16, 2026, the board of directors scheduled a meeting to consider a final dividend for the 2025-26 fiscal year. Throughout the week, market reports highlighted that the company's shares faced a muted performance in 2026, leading to a 'Hold' rating from MarketsMOJO on April 17, 2026. These updates followed ongoing investor scrutiny regarding the firm's recent quarterly results and broader operational risks within the pharmaceutical sector.
Events
Dr. Reddy’s Laboratories has scheduled a board meeting for April 16, 2026, to consider the recommendation of a final dividend for the financial year 2025-26.
Dr. Reddy’s Laboratories’ Russian subsidiary has been issued a final VAT penalty of RUB 9.27 million (approximately ₹11.40 million) by the Russian Federal Tax Service. The company stated that this penalty has no material impact on its financial or operational activities.
Dr. Reddy’s Laboratories has submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. This filing confirms that the company's Registrar and Share Transfer Agent has processed all dematerialization requests within the prescribed timelines.
Dr. Reddy’s Laboratories has entered into an agreement to sell its entire shareholding in its wholly owned subsidiary, Svaas Wellness Limited, to Enspirit Technology Services Private Limited for ₹2.23 crore. This divestment results in Svaas Wellness Limited ceasing to be a subsidiary of the company.
Dr. Reddy’s Laboratories has allotted 3,675 equity shares of Re. 1 each to eligible employees following the exercise of stock options under its 2007 ESOP scheme. This issuance increases the company's total paid-up share capital.
India Ratings and Research assigned and affirmed 'IND AA+/Stable/IND A1+' ratings on Dr. Reddy's Laboratories' bank loan facilities. The action reflects the company's strong US market position, healthy credit metrics, and adequate liquidity despite some margin pressure.
Dr. Reddy’s Laboratories’ Russian subsidiary has been issued a final VAT penalty of RUB 9.27 million (approximately ₹11.40 million) by the Russian Federal Tax Service. The company stated that this penalty has no material impact on its financial or operational activities.
Dr. Reddy’s Laboratories has submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. This filing confirms that the company's Registrar and Share Transfer Agent has processed all dematerialization requests within the prescribed timelines.
Dr. Reddy’s Laboratories has entered into an agreement to sell its entire shareholding in its wholly owned subsidiary, Svaas Wellness Limited, to Enspirit Technology Services Private Limited for ₹2.23 crore. This divestment results in Svaas Wellness Limited ceasing to be a subsidiary of the company.
Dr. Reddy’s Laboratories has allotted 3,675 equity shares of Re. 1 each to eligible employees following the exercise of stock options under its 2007 ESOP scheme. This issuance increases the company's total paid-up share capital.
India Ratings and Research assigned and affirmed 'IND AA+/Stable/IND A1+' ratings on Dr. Reddy's Laboratories' bank loan facilities. The action reflects the company's strong US market position, healthy credit metrics, and adequate liquidity despite some margin pressure.
Weekly Snapshot
Highlights
- The stock price saw a minor increase of 0.28% this week, accompanied by a significant 27.43% rise in trading volume.
- Technical indicators show the stock is in a neutral phase, with the Relative Strength Index (RSI, a measure of momentum) at 47.42.
- Dr. Reddy's Laboratories scheduled a board meeting for April 16, 2026, to discuss a final dividend for the 2025-26 fiscal year.
- The company's Russian subsidiary received a final VAT penalty of RUB 9.27 million, which the firm stated has no material impact on operations.
- MarketsMOJO assigned a 'Hold' rating to the stock on April 17, 2026, following a period of muted performance throughout the year.
What This Means
Dr. Reddy's Laboratories experienced a week of consolidation, with the stock price trading near its 50-day and 200-day moving averages. While trading volume increased, technical indicators like the RSI remain in neutral territory, reflecting a lack of strong directional momentum. The company continues to manage operational matters, such as the recent tax penalty in Russia and the divestment of Svaas Wellness, while preparing for dividend discussions. Long-term financial data shows a history of revenue growth, though recent quarterly results have indicated a temporary softening in net profit.
Latest Quarter Info
For the quarter ending December 2025, the company reported revenue of 8,753, reflecting a modest year-over-year growth of 4.4% despite a slight sequential contraction of 0.8%. Operating profitability remains a core pillar, with an operating margin of 22% supported by 1,888 in operating profit. However, the bottom line faces pressure, as net profit declined by 15.2% year-over-year and 11% sequentially, resulting in an EPS of 14.5. This divergence between top-line resilience and bottom-line contraction is influenced by non-operating factors, including depreciation costs of 521 and a 23% tax rate. While revenue momentum shows stability on an annual basis, the current profitability trend highlights a need to manage rising operational and financial overheads to align net earnings with broader sales performance.